Section
Recent real-world data from the US and France indicate that while both maternal RSV vaccination and nirsevimab are effective, nirsevimab may offer superior protection against hospitalization and intensive care admission for infants in their
The RECOVERY trial demonstrates that sotrovimab significantly reduces 28-day mortality in hospitalized COVID-19 patients with high baseline serum antigen levels, highlighting the potential for biomarker-guided monoclonal antibody therapy de
A clinical trial assessing germicidal UV light in long-term care shows modest reduction in acute respiratory infections, suggesting UV technology as a supportive tool in infection control for older adults.
This randomized clinical trial explored if next-day HIV viral load results improve linkage to care. While overall linkage rates remained unchanged, the intervention significantly accelerated care initiation for individuals already living wi
A new influenza strain, Subclade K (AH3N2 J.2.4.1), is dominating Europe’s flu season with a 90% prevalence rate. Experts emphasize that while the strain is highly transmissible, vaccination remains the most effective tool for prevent
This interim analysis of the phase 4 EPI-MAL-003 study demonstrates that the RTS,S/AS01E malaria vaccine significantly reduces severe malaria, malaria-related hospitalizations, and all-cause hospitalizations in real-world clinical settings
A double-blind RCT in Chile demonstrates that a 14-day optimized bismuth quadruple therapy achieves a 95% eradication rate for Helicobacter pylori, significantly outperforming standard triple therapy without increasing the burden of adverse
A systematic review identifies high HIV positivity (5.9%) among TB household contacts, highlighting the critical need to integrate HIV testing into routine TB screening to address the diagnostic gap in high-burden settings.
An international evaluation of the SEIZURE score reveals limited global predictive power for acute seizures in encephalitis. While the tool performs well in Western Europe, particularly Portugal, its utility elsewhere is hampered by etiolog
The DANFLU-2 trial found that while high-dose influenza vaccines significantly reduced influenza-specific hospitalizations in older adults, they did not reach statistical significance for the combined primary endpoint of influenza or pneumo
A multinational randomized trial found that adding high‑dose oral rifampin (total 35 mg/kg for 8 weeks) to standard therapy did not reduce 6‑month mortality in adults with tuberculous meningitis and was associated with more drug‑induced liv
Cochrane review shows prophylactic antibiotics may reduce SSI risk in peripheral arterial reconstruction; closed incision negative pressure therapy offers possible benefit but evidence is low.
A large network meta‑analysis confirms HPV vaccines effectively reduce CIN2+ and anogenital warts, with no major safety concerns.
A large multicenter Brazilian cohort found that ICU-level structure and process measures — staffing, prevention protocols, hand hygiene training, visitation policies, and specific clinical roles — explain substantial between-hospital variab
A 50‑ICU nested cohort from the IMPACTO‑MR platform links ICU-level structure and care processes to substantially different ventilator‑associated pneumonia and central line‑associated bloodstream infection rates, highlighting modifiable ins
The ImmunoSep randomized trial found that biomarker-guided immunotherapy (anakinra for macrophage activation‑like syndrome; interferon‑γ for sepsis‑induced immunoparalysis) improved organ dysfunction by day 9 versus placebo, though 28‑day m
A phase 2a human challenge trial found a nucleoside‑modified mRNA influenza vaccine provided complete protection against symptomatic and febrile A/H1N1 infection versus unvaccinated controls and reduced viral load versus control and QIV, wi
A randomized trial of 20,330 girls 12–16 years shows one dose of bivalent or nonavalent HPV vaccine prevents persistent HPV16/18 infection as effectively as two doses over 5 years, with high effectiveness and no safety signals.
A multicentre phase 1 trial in healthy US adults found nOPV1 and nOPV3 were well tolerated and induced robust homotypic neutralising antibody responses with shedding profiles similar to Sabin monovalent OPV, supporting progression to phase
A multicentre phase 3 trial shows single‑ and multidose EuTCV (Vi‑CRM197) are immunologically non‑inferior to Typbar TCV in infants 9–12 months, with comparable safety and reactogenicity across ages — supporting WHO prequalification.
